192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S140-S141

  Mok, T ^a   Schmid, P ^b   Aren O ^c   Arrieta, O ^d   Gottfried, M ^e   Jazieh, A R ^f   Ramlau, R ^g   Timcheva, K ^h   Martin, C ⁱ   McIntosh, S ^j  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Department of Oncology   (Chile)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e MEIR MEDICAL CENTER   (Israel)

^f KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h National Oncological Medical Center   (Bulgaria)

ⁱ INSTITUTO ALEXANDER FLEMING   (Argentina)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DURVALUMAB; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT OUTCOME;

EID: 85017731911     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30301-X     Document Type: Article

References (0)